| Publications | PubMed=4549213; DOI=10.1002/ijc.2910140402
de Vries J.E., Cornain S., Rumke P.
Cytotoxity of non-T versus T-lymphocytes from melanoma patients and healthy donors on short- and long-term cultured melanoma cells.
Int. J. Cancer 14:427-434(1974) PubMed=1079770; DOI=10.1016/0014-2964(75)90007-9
Vanwijck R., Bouillenne C., Malek-Mansour S.
Potentiation and arming of lymphocyte mediated immunity by sera from melanoma patients.
Eur. J. Cancer 11:267-276(1975) PubMed=1101782; DOI=10.1111/j.1749-6632.1975.tb29200.x
The T.H., Huiges H.A., Schraffordt Koops H., Lamberts H.B., Nieweg H.O.
Surface antigens on cultured malignant melanoma cells as detected by a membrane immunofluorescence method with human sera. Lack of tumor-specific reactions on melanoma lines.
Ann. N. Y. Acad. Sci. 254:528-540(1975) PubMed=1104492; DOI=10.1002/ijc.2910160612
Cornain S., de Vries J.E., Collard J.G., Vennegoor C., van Wingerden I., Rumke P.
Antibodies and antigen expression in human melanoma detected by the immune adherence test.
Int. J. Cancer 16:981-997(1975) PubMed=6090953; DOI=10.1038/311671a0
Padua R.A., Barrass N.C., Currie G.A.
A novel transforming gene in a human malignant melanoma cell line.
Nature 311:671-673(1984) PubMed=1697409
Chenevix-Trench G., Martin N.G., Ellem K.A.O.
Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53.
Oncogene 5:1187-1193(1990) PubMed=9354451
Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M., Gabrielli B.G., Parsons P.G., Hayward N.K.
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997) PubMed=23039341; DOI=10.1186/1476-4598-11-75; PMCID=PMC3554420
Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J., Nomoto K., Pollock P.M.
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol. Cancer 11:75.1-75.15(2012) |
|---|
